Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network
HENDERSON, Nev., Jan. 12, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. ("IDEXX") reference laboratory network in the U.S.
Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "IDEXX is a global leader in pet healthcare innovation and well-positioned to roll out the IDEXX Nu.Q® Canine Cancer Screen worldwide. It is a simple, cost effective, easy to use blood test for screening older or 'at risk' dogs.
"Our Nucleosomics™ technology is easy to incorporate into annual wellness visits to support veterinarians in their clinical decision-making, enable earlier detection and treatment of cancer and improve the health and wellbeing of pets and pet owners.
"IDEXX's launch of the Nu.Q® Canine Cancer Screen in the U.S. this week, under our previously announced supply agreement¹, ultimately provides worldwide customer reach through its global reference laboratory network as we continue to commercialize our transformational Nu.Q® technology within the companion animal healthcare sector, and capitalize on the significant opportunities available."
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com.
Note to editors:
1. Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test. Oct 20 2022
2. Findings from a clinical study conducted by Volition and Professor Wilson-Robles and the team at Texas A&M University, peer-reviewed and published in August 2022, showed that:
- Volition's Nu.Q® Vet Cancer Test detected 76% of systemic cancers ( including lymphoma, hemangiosarcoma, and histiocytic sarcoma) at 97% specificity versus control.
About the U.S. market segment
- The Veterinary Cancer Society estimates that 1 in 4 dogs will develop cancer at some point, and almost 50% of dogs over the age of 10 will develop cancer.
- In a Pet Owner Survey conducted in June/ July 2021 by The Human Animal Bond Research Institute (HABRI) Foundation, 95% of pet owners Strongly Agreed/Agreed that "My pet is part of my family".
- According to IDEXX, just under 50% of dogs have preventative care visits each year.
- Approximately six million new cancer diagnoses are made in dogs in the U.S. alone each year, and according to IDEXX its team of global pathologists reviews over one million suspected cancer case submissions in companion animals annually.
- IDEXX estimates that its companion animal practice growth quarterly updates reflected ~ 9% wellness visit growth in 2021 and relative strength in 2022 despite a pullback in veterinary clinic capacity.
Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. This website address is included in this document as an inactive textual reference only.
Louise Batchelor/Debra Daglish, Volition, firstname.lastname@example.org +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's estimated market opportunity, Volition's expectations related to the potential benefits under the supply agreement with IDEXX , the effectiveness of Volition's blood-based diagnostic, prognostic and disease monitoring tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-announces-expansion-of-availability-of-the-nuq-vet-cancer-test-through-idexxs-reference-laboratory-network-301720349.html
SOURCE VolitionRx Limited
Released January 12, 2023